| Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions M Castella, A Boronat, R Martín-Ibáñez, V Rodríguez, G Suñé, ... Molecular Therapy-Methods & Clinical Development 12, 134-144, 2019 | 124 | 2019 |
| Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma A Moros, V Rodriguez, I Saborit-Villarroya, A Montraveta, P Balsas, ... Leukemia 28 (10), 2049, 2014 | 120 | 2014 |
| The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma A Esteve-Arenys, JG Valero, A Chamorro-Jorganes, D Gonzalez, ... Oncogene, 1, 2018 | 93 | 2018 |
| The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia S Xargay-Torrent, M López-Guerra, L Rosich, A Montraveta, J Roldán, ... Oncotarget 6 (26), 22734, 2015 | 76 | 2015 |
| Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs GD Peluffo, I Stillitani, VA Rodríguez, MJ Diament, SM Klein International journal of cancer 110 (6), 825-830, 2004 | 66 | 2004 |
| The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia A Matas-Céspedes, A Vidal-Crespo, V Rodriguez, N Villamor, J Delgado, ... Clinical Cancer Research 23 (6), 1493-1505, 2017 | 65 | 2017 |
| The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling T Díaz, V Rodríguez, E Lozano, MP Mena, M Calderón, L Rosiñol, ... haematologica 102 (10), 1776-1784, 2017 | 62 | 2017 |
| Inducible ablation of dopamine D2 receptors in adult mice impairs locomotion, motor skill learning and leads to severe parkinsonism EP Bello, R Casas-Cordero, GL Galiñanes, E Casey, MA Belluscio, ... Molecular psychiatry 22 (4), 595, 2017 | 60 | 2017 |
| Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells S Body, A Esteve-Arenys, H Miloudi, C Recasens-Zorzo, G Tchakarska, ... Scientific Reports 7 (1), 13946, 2017 | 55 | 2017 |
| The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma JG Valero, A Matas-Céspedes, F Arenas, V Rodriguez, J Carreras, ... Leukemia 35 (9), 2635-2649, 2021 | 53 | 2021 |
| Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. PGP Vidal-Crespo A1, Matas-Céspedes A2, Rodriguez V3, Rossi C4, Valero JG3 ... Haematologica., 2019 | 45 | 2019 |
| Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer C Lodillinsky, V Rodriguez, L Vauthay, E Sandes, A Casabé, AM Eiján The Journal of urology 182 (2), 749-755, 2009 | 43 | 2009 |
| Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy E Silkenstedt, F Arenas, B Colom-Sanmartí, S Xargay-Torrent, M Higashi, ... Journal of Experimental & Clinical Cancer Research 38, 1-15, 2019 | 39 | 2019 |
| Safety assessment of nonbrowning potatoes: opening the discussion about the relevance of substantial equivalence on next generation biotech crops B Llorente, GD Alonso, F Bravo‐Almonacid, V Rodríguez, MG López, ... Plant biotechnology journal 9 (2), 136-150, 2011 | 39 | 2011 |
| Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib) A Matas-Céspedes, V Rodriguez, SG Kalko, A Vidal-Crespo, L Rosich, ... Clinical Cancer Research 20 (13), 3458-3471, 2014 | 35 | 2014 |
| Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the … O Pontiggia, V Rodriguez, V Fabris, D Raffo, V Bumaschny, G Fiszman, ... Breast cancer research and treatment 116 (2), 247-255, 2009 | 32 | 2009 |
| Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma E Lozano, T Díaz, MP Mena, G Suñe, X Calvo, M Calderón, L Pérez-Amill, ... The Journal of Immunology 200 (8), 2581-2591, 2018 | 27 | 2018 |
| Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy V Ortiz-Maldonado, S Rives, M Español-Rego, A Alonso-Saladrigues, ... Journal for immunotherapy of cancer 9 (12), 2021 | 25 | 2021 |
| Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma C Recasens-Zorzo, T Cardesa-Salzmann, P Petazzi, L Ros-Blanco, ... Haematologica, haematol. 2017.180505, 2018 | 25 | 2018 |
| A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice M Simian, T Manzur, V Rodriguez, EB de Kier Joffé, S Klein Breast cancer research and treatment 113 (1), 1-8, 2009 | 25 | 2009 |
